Skip to content
The Policy VaultThe Policy Vault

tobramycin injectionCareFirst (Caremark)

C. difficile-associated diarrhea (oral vancomycin)

Initial criteria

  • The requested drug will NOT be used intranasally or in a footbath
  • The requested drug is being prescribed for an FDA-approved indication or an indication supported in the compendia of current literature (examples: AHFS, Micromedex, current accepted guidelines)
  • The infection is proven or strongly suspected to be caused by susceptible microorganisms
  • The patient cannot be treated with oral therapy OR the request is for vancomycin to be taken orally for the treatment of C. difficile-associated diarrhea or for staphylococcal enterocolitis

Approval duration

serious, chronic, recurring infection: 12 months; other indications: 3 months